Guidance
Evidence-based recommendations developed by independent committees, including professionals and lay members, and consulted on by stakeholders.
Get involved
We want you to be involved in our work. Tell us what matters to you, your organisation or your community.
There are many ways you can get involved as a healthcare professional or a member of the public.
About us
Find out more about
and how we support
The NICE strategy 2021 to 2026 sets out an ambitious vision for our future.
Latest news
-
NICE has today (26 October) published draft guidance for public consultation which does not recommend tucatinib (also called TUKYSA and made by Seagen Inc), in combination with trastuzumab and capecitabine, for some types of breast cancer that has spread.
-
NICE is advising doctors, nurses and pharmacists to discuss with patients the risks of prescribing them medicines including opioids, sleeping pills and antidepressants.
-
NICE has today (20 October 2021) announced the next steps for publication of its updated guideline on the diagnosis and management of myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS).
-
Online event will lift the lid on how the two organisations worked together during the pandemic
Explore NICE
Into practice
Resources to help you use our guidance and quality standards
Financial planning
Advice and tools to help you make the best use of your resources
Antimicrobial resistance
View our antimicrobial prescribing guidelines
Our role in patient safety
Our guidelines make evidence-based, best practice recommendations.
Find journals and databases
Access to a range of journals and other evidence-based resources.